Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Phase 1 Terminated
10 enrolled
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Phase 2 Terminated
6 enrolled 7 charts
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
Phase 2 Completed
100 enrolled 7 charts
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Phase 1/2 Withdrawn
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
Phase 2 Completed
60 enrolled
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 2 Completed
49 enrolled 6 charts
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
68 enrolled 7 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Phase 1/2 Completed
150 enrolled 9 charts
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled 9 charts
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
Phase 2 Completed
60 enrolled
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
Alemtuzumab and Pentostatin In T-cell Neoplasms
Phase 2 Terminated
26 enrolled 5 charts
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 2 Completed